SFC
BMRN icon

SYM Financial Corp’s BioMarin Pharmaceuticals BMRN Stock Holding History

SYM Financial Corp’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,235
Closed -$239K – 535
2026
Q1 		$239K Sell
4,235
-286
-6% -$16.7K 0.02% 274
2025
Q4 		$269K Sell
4,521
-71
-2% -$3.87K 0.03% 256
2025
Q3 		$249K Buy
+4,592
New +$263K 0.03% 257
2025
Q2 		– Sell
-3,466
Closed -$245K – 423
2025
Q1 		$245K Buy
+3,466
New +$233K 0.03% 212

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SYM Financial Corp's BMRN Position: Q2 2026 in Review

SYM Financial Corp sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 4,235 shares — an estimated $239K sold.

SYM Financial Corp first reported a position in BMRN in Q1 2025 and held it in 4 quarters. The position peaked at $269K in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • SYM Financial Corp reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • SYM Financial Corp sold 4,235 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $239K.
  • SYM Financial Corp first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • SYM Financial Corp's BioMarin Pharmaceuticals position peaked at $269K in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on SYM Financial Corp's 13F filing for Q2 2026, filed 4 Aug 2026.